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Letter	  to	  the	  Editor	  24	  
Dear Editor, 25	  
 26	  
We observed very high uterine [18F]-fluorodeoxyglucose (FDG) uptake on positron 27	  
emission tomography (PET) in what proved to be a benign uterine leiomyoma. Although 28	  
clinically apparent in 25% of women (1) and prevalent in up to 77% (2), only incidentally 29	  
this phenomenon is described. Here we present a case of a 49-year old woman. 30	  
Our patient underwent an FDG-PET/CT for follow-up of an infectious focus on 31	  
the lower back. Apart from a metabolically active lymph node and bone marrow, it revealed 32	  
a ~9.6cm large, inhomogeneous but sharply demarcated FDG-avid lesion in the posterior 33	  
uterine wall (figure 1). The lesion was ultrasonographically a typical large leiomyoma.  34	  
An abdominal hysterectomy was performed for lumbago and anaemia due to 35	  
meno-metrorrhagia. Histopathological examination revealed an enlarged uterus with an 36	  
intramural leiomyoma of 7.8 cm in diameter and multiple small subserosal leiomyomas the 37	  
size below the resolution of the PET/CT scanner. Microscopy showed the typical image of 38	  
a leiomyoma, without signs of necrosis, haemorrhage, atypia or inflammation. There was 39	  
no cervical atypia and the endometrium was thin (<1mm) and showed some changes 40	  
corresponding to progestagen suppletion. 41	  
In search of an explanation for the high FDG-uptake, sections of the anterior - on 42	  
PET normal - uterine myometrium, were compared to sections of the leiomyoma. 43	  
Immunohistochemical staining of markers for proliferation, inflammation, hypoxia, 44	  
apoptosis, vascularity, glucose metabolism and glycogen content was quantified. This 45	  
quantification demonstrated a slight increase in proliferation and glycogen content . 46	  
Incidentally found leiomyomas are occasionally reported to have elevated FDG-47	  
uptake (SUV 6.0-16) (3, 4). Retrospective analysis of screening FDG-PET in 589 healthy 48	  
women found increased FDG-uptake due to leiomyomas in 22 females of which only 14% 49	  
showed FDG-uptake higher than the liver (5). A screening FDG-PET in 1357 healthy 50	  
women found an standardized uptake value (SUV) larger than 3.0 in 10% of the 51	  
leiomyomas in premenopausal women and in only 1.2% in postmenopausal women (6). A 52	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prospective study of 61 proven leiomyomas showed that 17% have an SUVmax higher than 53	  
2.5, but only one had an SUV larger than 5.0 (7). 54	  
The differential diagnosis of increased uterine FDG-uptake should include the 55	  
menstrual and ovulation phase of the menstrual cycle, menorrhagia, postpartum changes, 56	  
atypical polypoid adenomyomas and IUDs. The SUV in leiomyosarcoma is significantly 57	  
higher than in leiomyomas but the overlap limits its ability to distinguish these in individual 58	  
patients (8). 59	  
The reason for enhanced FDG-uptake in leiomyomas is suggested to be related to 60	  
the high levels of cervical and endometrial tissue glycogen in a myomatous uterus, the 61	  
increased blood fraction and the proliferation of the smooth muscle cells due to increased 62	  
metabolic need. Finally, it is measured that leiomyomas have severe hypoxia, even though 63	  
no stress-reaction could be quantified by HIF-1α, CAIX or GLUT1 expression (9).  64	  
To clinicians and nuclear medicine specialists it is important to be aware of the 65	  
fact that benign leiomyomas of the uterus may rarely show high FDG-uptake. Although 66	  
leiomyosarcomas show higher FDG-uptake than leiomyomas, it does not distinguish benign 67	  
and malignant disease.	   	  68	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Figures	  74	  
Figure 1: [18F]-fluorodeoxyglucose (FDG) positron emission tomography with non-75	  
diagnostic, low-dose x-ray computed tomography performed in a 49-year-old woman with 76	  
a history of soft tissue infection of the lower back. Arrow: intense FDG-uptake (max SUV: 77	  
12.7, mean SUV: 8.4) in the enlarged uterus, posterior wall. Arrowhead: urinary bladder. 78	  
SUV: standardized uptake value, parameter representing the relative increase of the 79	  
regional uptake of the tracer above expected from homogenous distribution over the body.  80	  
  81	  
	   -­‐	  6	  -­‐	  
	  
References	  82	  
1.	   Buttram	   VC,	   Jr.,	   Reiter	   RC.	   Uterine	   leiomyomata:	   etiology,	  83	  
symptomatology,	  and	  management.	  Fertility	  and	  sterility.	  1981	  Oct;36(4):433-­‐45.	  84	  
2.	   Cramer	   SF,	   Patel	   A.	   The	   frequency	   of	   uterine	   leiomyomas.	   American	  85	  
journal	  of	  clinical	  pathology.	  1990	  Oct;94(4):435-­‐8.	  86	  
3.	   Ak	   I,	   Ozalp	   S,	   Yalcin	   OT,	   Zor	   E,	   Vardareli	   E.	   Uptake	   of	   2-­‐[18F]fluoro-­‐2-­‐87	  
deoxy-­‐D-­‐glucose	   in	   uterine	   leiomyoma:	   imaging	   of	   four	   patients	   by	   coincidence	  88	  
positron	   emission	   tomography.	   Nuclear	   medicine	   communications.	   2004	  89	  
Sep;25(9):941-­‐5.	  90	  
4.	   Chura	  JC,	  Truskinovsky	  AM,	  Judson	  PL,	  Johnson	  L,	  Geller	  MA,	  Downs	  LS,	  Jr.	  91	  
Positron	   emission	   tomography	   and	   leiomyomas:	   clinicopathologic	   analysis	   of	   3	  92	  
cases	   of	   PET	   scan-­‐positive	   leiomyomas	   and	   literature	   review.	   Gynecologic	  93	  
oncology.	  2007	  Jan;104(1):247-­‐52.	  94	  
5.	   Lin	  CY,	  Ding	  HJ,	  Chen	  YK,	  Liu	  CS,	  Lin	  CC,	  Kao	  CH.	  F-­‐18	  FDG	  PET	  in	  detecting	  95	  
uterine	  leiomyoma.	  Clinical	  imaging.	  2008	  Jan-­‐Feb;32(1):38-­‐41.	  96	  
6.	   Nishizawa	  S,	  Inubushi	  M,	  Kido	  A,	  Miyagawa	  M,	  Inoue	  T,	  Shinohara	  K,	  et	  al.	  97	  
Incidence	  and	  characteristics	  of	  uterine	   leiomyomas	  with	  FDG	  uptake.	  Annals	  of	  98	  
nuclear	  medicine.	  2008	  Nov;22(9):803-­‐10.	  99	  
7.	   Kitajima	   K,	   Murakami	   K,	   Yamasaki	   E,	   Kaji	   Y,	   Sugimura	   K.	   Standardized	  100	  
uptake	   values	   of	   uterine	   leiomyoma	   with	   18F-­‐FDG	   PET/CT:	   variation	   with	   age,	  101	  
size,	   degeneration,	   and	   contrast	   enhancement	   on	   MRI.	   Annals	   of	   nuclear	  102	  
medicine.	  2008	  Jul;22(6):505-­‐12.	  103	  
8.	   Tsujikawa	  T,	  Yoshida	  Y,	  Mori	  T,	  Kurokawa	  T,	  Fujibayashi	  Y,	  Kotsuji	  F,	  et	  al.	  104	  
Uterine	   tumors:	   pathophysiologic	   imaging	   with	   16alpha-­‐[18F]fluoro-­‐17beta-­‐105	  
estradiol	   and	   18F	   fluorodeoxyglucose	   PET-­‐-­‐initial	   experience.	   Radiology.	   2008	  106	  
Aug;248(2):599-­‐605.	  107	  
9.	   Shida	  M,	  Murakami	  M,	  Tsukada	  H,	  Ishiguro	  Y,	  Kikuchi	  K,	  Yamashita	  E,	  et	  al.	  108	  
F-­‐18	   fluorodeoxyglucose	   uptake	   in	   leiomyomatous	   uterus.	   Int	   J	   Gynecol	   Cancer.	  109	  
2007	  Jan-­‐Feb;17(1):285-­‐90. 110	  

